earnings
confidence high
sentiment positive
materiality 0.85
Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook
Niagen Bioscience, Inc.
2025-Q1 EPS reported
$0.06
revenue$30,481,000
- Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).
- Net income of $5.1M ($0.07 EPS) vs net loss of $0.5M in Q1 2024.
- Adjusted EBITDA of $4.9M, up from $0.7M in prior year.
- Raised FY2025 outlook: net sales growth 20-25% (prev ~18%); adj G&A $7-8M.
- Name change to Niagen Bioscience, ticker NAGE effective Mar 19; new patent for NR salt forms.